Trial · NCT00616642
Rosiglitazone in Treating Patients With Pituitary Tumors
NCT00616642, Phase 2, Terminated, Jonsson Comprehensive Cancer Center; results first posted 2013-04-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rosiglitazone in Treating Patients With Pituitary Tumors. Trials, record NCT00616642. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00616642
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rosiglitazone in Treating Patients With Pituitary Tumors
- NCT number
- NCT00616642
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- rosiglitazone maleate
- First posted
- 2008-02-15
- Last updated
- 2020-08-14
- Results first posted
- 2013-04-15
- Limitations and caveats
- Recruitment was the main limitation. Patients were available but were not interested in the study due to possible side effects of the study drug.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of Rosiglitazone Maleate on Cushing Disease | 12 months | Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of Rosiglitazone Maleate on Cushing Disease | 12 months | No data was analyzed for this outcome measure as there was insufficient data to perform analysis. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 (ACTH-secreting Adenomas) | 0 | |
| Overall Study | STARTED | Group 2 (Non-secreting Macroadenomas) | 1 | |
| Overall Study | COMPLETED | Group 1 (ACTH-secreting Adenomas) | 0 | |
| Overall Study | COMPLETED | Group 2 (Non-secreting Macroadenomas) | 0 | |
| Overall Study | NOT COMPLETED | Group 1 (ACTH-secreting Adenomas) | 0 | |
| Overall Study | NOT COMPLETED | Group 2 (Non-secreting Macroadenomas) | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 1 (ACTH-secreting Adenomas) | ||
| Total, all-cause mortality | Group 2 (Non-secreting Macroadenomas) | ||
| Total, other adverse events | Group 1 (ACTH-secreting Adenomas) | 0 | 0 |
| Total, other adverse events | Group 2 (Non-secreting Macroadenomas) | 0 | 1 |
| Total, serious adverse events | Group 1 (ACTH-secreting Adenomas) | 0 | 0 |
| Total, serious adverse events | Group 2 (Non-secreting Macroadenomas) | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016042 | Cancer Center Support Grant | TEITELL, MICHAEL A | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00616642
GET https://conductscience.org/api/trials/v1/NCT00616642/registered